

„New vision for primary health
care and sustainable development“



WONCA 2025

25TH WONCA WORLD CONFERENCE

17 – 21 SEPTEMBER 2025

LISBOA CONGRESS CENTRE – CCL

#woncaworld2025

www.woncaworld2025.org



CONFLICT OF INTEREST (COI)

I have no potential conflict of interest to report

Semaglutide and Acenocoumarol Interaction: A Case Report

WONCA Lisbon 2025

Girard Aurore, MD, CAMG - UCLouvain, Belgium

Introduction

- Semaglutide: GLP-1 receptor agonist (injectable & oral)
- Vitamin K antagonists (VKA): INR-sensitive

Case explores INR instability after switch from injectable to oral semaglutide


- Generally safe with few drug-drug interactions

Case Report

- 78-year-old man
- T2DM, rheumatoid arthritis, thyroidectomy
 - Treatments:
 - acenocoumarol,
 - semaglutide
 - telmisartan/HCTZ
 - levothyroxine


Case Report

- After switch from injectable to oral : INR fluctuations (sub- & supratherapeutic)
- No changes in diet, adherence, or liver function



Case Report

Return to injectable semaglutide
→ rapid INR stabilization within a few days



semaglutide

Discussion

- Oral semaglutide may alter drug absorption & pharmacokinetics
 - Possible interaction with VKA metabolism or absorption
 - No direct pharmacological interaction known
- Clinical implication: unstable INR after formulation switch

Key considerations

Pharmacokinetics:

Oral semaglutide absorption relies on SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), which modify gastric pH.
This may influence absorption of other drugs (e.g., VKAs).

Clinical factors:

Advanced age and polypharmacy increase the risk of unexpected interactions.

Key considerations

Literature:

Rare case reports of unstable INR after switching from injectable → oral; underscores need for stronger pharmacovigilance.

Research:

Further studies needed on SNAC's impact and on the effect of oral GLP-1 analogues on the bioavailability of VKAs and other sensitive drugs (levothyroxine, digoxin).

Clinical Implications

- Monitor INR closely in anticoagulated patients when switching GLP-1 formulations
 - Consider maintaining injectable form in VKA users if stable
 - More research needed on oral semaglutide's absorption interactions
- Highlights importance of vigilance in multimorbid elderly patients

Conclusion

- Case demonstrates possible impact of oral semaglutide on INR stability
- Highlights need for caution when changing GLP-1 formulations
 - Further studies required
- Practical tip: monitor INR after semaglutide formulation changes

Semaglutide and Acenocoumarol Interaction: A Case Report - Thank you

WONCA Lisbon 2025

Girard Aurore, MD, CAMG - UCLouvain, Belgium

